ECTRIMS 2024: Tolebrutinib may target smoldering inflammation
Sep 23, 2024 · Sanofi’s tolebrutinib significantly delayed disability progression, by 31%, and increased the rates of disability improvement compared with a placebo in people with …
Sanofi's tolebrutinib cuts MS progression by 31% in trial
Nov 5, 2024 · Sanofi has bolstered the case for its oral BTK inhibitor tolebrutinib as a treatment for multiple sclerosis (MS), due to be filed for approval in the latter half of this year, with new data …
Sanofi lifts lid on data behind tolebrutinib’s mixed MS studies
Sep 20, 2024 · Sanofi has shared data from the phase 3 HERCULES trial that could rescue its multiple sclerosis (MS) drug candidate tolebrutinib, linking the BTK inhibitor to a 31% delay in …
Press Room - Sanofi US News
Sep 20, 2024 · Tolebrutinib is an investigational, oral, brain-penetrant, and bioactive Bruton’s tyrosine kinase (BTK) inhibitor that achieves CSF concentrations predicted to modulate B …
Tolebrutinib Looks Promising for Patients With Non-Relapsing …
Oct 15, 2024 · Tolebrutinib was found to delay disability progression in patients with non-relapsing secondary progressive multiple sclerosis (nrSPMS), according to results from the HERCULES …
Tolebrutinib Long-term Data Continue to Show the BTK Inhibitor …
Apr 25, 2023 · Tolebrutinib is a Bruton tyrosine kinase (BTK) inhibitor that is being investigated for use in patients who have relapsing multiple sclerosis (MS); investigators presented safety data …
Multiple sclerosis pill succeeds in key trial, Sanofi says - STAT
Sep 2, 2024 · Sanofi said an oral treatment for multiple sclerosis, tolebrutinib, met its key goal in a Phase 3 study, potentially clearing the way for regulatory approval, although in two other …
Feb 23, 2023 · New data for tolebrutinib, Sanofi’s investigational oral Bruton’s tyrosine kinase (BTK) inhibitor for the treatment of multiple sclerosis (MS), showed a significant effect on key …
BTK Inhibitor Tolebrutinib Slows Disability Progression in Phase 3 ...
Sep 3, 2024 · Tolebrutinib, a brain-penetrant BTK inhibitor, achieved the primary endpoint in the HERCULES study, significantly reducing disability accumulation in patients with non-relapsing …
ECTRIMS 2023: Tolebrutinib show benefits for up to 3 years
Oct 16, 2023 · Treatment with tolebrutinib for up to nearly three years was tied to low relapse rates, stable disability, and few new brain lesions among people with relapsing forms of …
- Some results have been removed